Author's posts
We’re All Suffering From Something — Is This A Problem?
There are positive benefits associated with dissemination of population health statistics as they drive patient awareness. The concern, however, is that the data may not be sufficiently contextualized and therapeutic implications not made clear to the …
Increasing Numbers of Americans Want Single Payer, But Is That What They Want?
Single payer healthcare is gaining in popularity in recent polls conducted in the U.S. As an approach to healthcare, however, single payer is less translatable to the U.S. context than hybrid systems on the European continent.
Has Amyloid-Based Research Turned The Corner?
Biogen’s recently reported positive Phase 2 trial results for BAN2401 rekindle hopes for the amyloid hypothesis and also more widespread use of amyloid imaging radiopharmaceuticals.
Better U.S. Patient Access To Cancer Drugs Comes At A Price
On balance, access to cancer drugs is better in the U.S. More drugs get approved and at a faster pace, with fewer reimbursement restrictions, higher patient cost-sharing notwithstanding.
Changes To Drug Prices: Gestures And Real Policy Shifts
One-off drug price freezes are positive gestures with little overall impact. On the other hand, certain policy proposals outlined in the HHS Blueprint may produce structural changes.
Taking A Wider View Of Precision Oncology
In certain instances molecular profiles of tumors appear to be a necessary but insufficient condition for the success of targeted therapies. Precision medicine may need to be supplemented with clinically useful data outside of the narrow lens of geneti…
Right To Try For Some Raises False Hopes For Many
Right to Try for some raises false hopes for many. For many patients the bill will have no material effect.
Precision Medicine Success Hinges On Diagnostics’ Clinical Utility
Establishing clinical utility is crucial to ensuring a diagnostic’s reimbursement, which in turn facilitates uptake, not only of the diagnostic but also the precision therapeutic.
“Diseases Of Despair” Contribute To Declining U.S. Life Expectancy
Deaths from diseases of despair are contributing to a decline in U.S. life expectancy. Penny wise, pound foolish policies may lead to continued increasing numbers of deaths due to diseases of despair.
Bold Rx-To-OTC Switches On The Horizon? Naloxone, Perhaps
A regulatory framework is in place for additional Rx-to-OTC switches where appropriate, including the opioid overdose antidote naloxone. It is up to sponsors to work with the FDA to deliver more switched products.
